{"id":4922,"date":"2015-10-20T17:25:05","date_gmt":"2015-10-20T17:25:05","guid":{"rendered":"http:\/\/192.138.189.65\/~capregnancy\/?p=4922"},"modified":"2021-05-26T16:55:18","modified_gmt":"2021-05-26T16:55:18","slug":"the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment","status":"publish","type":"post","link":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/","title":{"rendered":"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment"},"content":{"rendered":"\n<p><em>Elyce Cardonick, Farhana Irfan, Natalie Torres<\/em><\/p>\n\n\n\n<p>ABSTRACT Introduction: Little is known about the effects stem cell mobilizers (GCSF) such as neulasta (pegfilgrastim) or neupogen (filgrastim) during pregnancy, and these are often withheld from women undergoing chemotherapy during pregnancy. Materials and Methods: Women receiving chemotherapy during pregnancy were identified from the Cancer and Pregnancy Registry maintained at Cooper University Hospital, Cooper Medical School at Rowan. 176 pregnant women who received chemotherapy were identified. Their oncologists were asked if neupogen or neulasta were \u201cprescribed when necessary;\u201d \u201cwere not necessary;\u201d or \u201cwere held due to pregnancy.\u201d Birth outcomes, white blood count at birth and pediatric health were compared between the group receiving Neupogen\/Neulasta (exposed) and a control group (unexposed), i.e. chemotherapy without neupogen\/neulasta). Independent T Test or Pearson Chi Square were implemented for statistical comparisons. Results: The mean gestational age at delivery was not significantly different between the exposed (35.4 \u00b1 2.8 weeks) and unexposed groups (35.9 \u00b1 2.8 weeks) p = 0.465. The mean birth weights were not significantly different, 2433 \u00b1 567 g (exposed) compared with 2673 \u00b1 723 g in unexposed group, p = 0.07. Nor was there a difference in congenital malformations: 11.7% versus 4.8%. p = 0.22. The incidence of non-iatrogenic preterm births or complications was not statistically different between groups. Mean WBC count in the exposed group was 13.04 \u00b1 5.0 cells per cubic millimeter of blood and in the unexposed group was 14.6 \u00b1 7.2, p = 0.24. Conclusion: We did not find a statistically significant difference in gestational age at birth, congenital anomalies, or birth weight, incidence of long term medical issues, mean WBC or neutropenia at birth between the newborns exposed to Neupogen\/ Neulasta with chemotherapy and newborns exposed to chemotherapy alone.<\/p>\n\n\n\n<!--more-->\n\n\n<div class=\"ead-preview\"><div class=\"ead-document\" style=\"position: relative;\"><div class=\"ead-iframe-wrapper\"><iframe src=\"\/\/docs.google.com\/viewer?url=http%3A%2F%2F192.138.189.65%2F~capregnancy%2Fwp-content%2Fuploads%2F2015%2F10%2F6-89012381.pdf&amp;embedded=true&amp;hl=en\" title=\"Embedded Document\" class=\"ead-iframe\" style=\"width: 100%;height: 750px;border: none;visibility: hidden;\"><\/iframe><\/div>\t\t\t<div class=\"ead-document-loading\" style=\"width:100%;height:100%;position:absolute;left:0;top:0;z-index:10;\">\n\t\t\t\t<div class=\"ead-loading-wrap\">\n\t\t\t\t\t<div class=\"ead-loading-main\">\n\t\t\t\t\t\t<div class=\"ead-loading\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/plugins\/embed-any-document\/images\/loading.svg\" width=\"55\" height=\"55\" alt=\"Loader\">\n\t\t\t\t\t\t\t<span>Loading...<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<div class=\"ead-loading-foot\">\n\t\t\t\t\t\t<div class=\"ead-loading-foot-title\">\n\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/plugins\/embed-any-document\/images\/EAD-logo.svg\" alt=\"EAD Logo\" width=\"36\" height=\"23\"\/>\n\t\t\t\t\t\t\t<span>Taking too long?<\/span>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<p>\n\t\t\t\t\t\t\t<div class=\"ead-document-btn ead-reload-btn\" role=\"button\">\n\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/plugins\/embed-any-document\/images\/reload.svg\" alt=\"Reload\" width=\"12\" height=\"12\"\/> Reload document\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t<span>|<\/span>\n\t\t\t\t\t\t\t<a href=\"http:\/\/192.138.189.65\/~capregnancy\/wp-content\/uploads\/2015\/10\/6-89012381.pdf\" class=\"ead-document-btn\" target=\"_blank\">\n\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/plugins\/embed-any-document\/images\/open.svg\" alt=\"Open\" width=\"12\" height=\"12\"\/> Open in new tab\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div><p class=\"embed_download\"><a href=\"http:\/\/192.138.189.65\/~capregnancy\/wp-content\/uploads\/2015\/10\/6-89012381.pdf\" download >Download <\/a><\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Elyce Cardonick, Farhana Irfan, Natalie Torres ABSTRACT Introduction: Little is known about the effects stem cell mobilizers (GCSF) such as neulasta (pegfilgrastim) or neupogen (filgrastim) during pregnancy, and these are often withheld from women undergoing chemotherapy during pregnancy. Materials and Methods: Women receiving chemotherapy during pregnancy were identified from the Cancer and Pregnancy Registry maintained [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":4968,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-4922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment - Cancer and Pregnancy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment - Cancer and Pregnancy\" \/>\n<meta property=\"og:description\" content=\"Elyce Cardonick, Farhana Irfan, Natalie Torres ABSTRACT Introduction: Little is known about the effects stem cell mobilizers (GCSF) such as neulasta (pegfilgrastim) or neupogen (filgrastim) during pregnancy, and these are often withheld from women undergoing chemotherapy during pregnancy. Materials and Methods: Women receiving chemotherapy during pregnancy were identified from the Cancer and Pregnancy Registry maintained [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Cancer and Pregnancy\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-20T17:25:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-05-26T16:55:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elyce Cardonick\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elyce Cardonick\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/\",\"url\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/\",\"name\":\"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment - Cancer and Pregnancy\",\"isPartOf\":{\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg\",\"datePublished\":\"2015-10-20T17:25:05+00:00\",\"dateModified\":\"2021-05-26T16:55:18+00:00\",\"author\":{\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/#\/schema\/person\/4193fb10f2572e3f8b9735bdc52aac25\"},\"breadcrumb\":{\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#primaryimage\",\"url\":\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg\",\"contentUrl\":\"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg\",\"width\":2500,\"height\":1667},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cancerandpregnancy.com\/staging\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/#website\",\"url\":\"https:\/\/cancerandpregnancy.com\/staging\/\",\"name\":\"Cancer and Pregnancy\",\"description\":\"Cancer and Pregnancy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cancerandpregnancy.com\/staging\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/#\/schema\/person\/4193fb10f2572e3f8b9735bdc52aac25\",\"name\":\"Elyce Cardonick\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cancerandpregnancy.com\/staging\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/460a3f26df5035cf9a773befb634bcc9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/460a3f26df5035cf9a773befb634bcc9?s=96&d=mm&r=g\",\"caption\":\"Elyce Cardonick\"},\"url\":\"https:\/\/cancerandpregnancy.com\/staging\/author\/ecardonick\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment - Cancer and Pregnancy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment - Cancer and Pregnancy","og_description":"Elyce Cardonick, Farhana Irfan, Natalie Torres ABSTRACT Introduction: Little is known about the effects stem cell mobilizers (GCSF) such as neulasta (pegfilgrastim) or neupogen (filgrastim) during pregnancy, and these are often withheld from women undergoing chemotherapy during pregnancy. Materials and Methods: Women receiving chemotherapy during pregnancy were identified from the Cancer and Pregnancy Registry maintained [&hellip;]","og_url":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/","og_site_name":"Cancer and Pregnancy","article_published_time":"2015-10-20T17:25:05+00:00","article_modified_time":"2021-05-26T16:55:18+00:00","og_image":[{"width":2500,"height":1667,"url":"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg","type":"image\/jpeg"}],"author":"Elyce Cardonick","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Elyce Cardonick","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/","url":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/","name":"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment - Cancer and Pregnancy","isPartOf":{"@id":"https:\/\/cancerandpregnancy.com\/staging\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg","datePublished":"2015-10-20T17:25:05+00:00","dateModified":"2021-05-26T16:55:18+00:00","author":{"@id":"https:\/\/cancerandpregnancy.com\/staging\/#\/schema\/person\/4193fb10f2572e3f8b9735bdc52aac25"},"breadcrumb":{"@id":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#primaryimage","url":"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg","contentUrl":"https:\/\/cancerandpregnancy.com\/staging\/wp-content\/uploads\/2015\/10\/preganancy-heart.jpg","width":2500,"height":1667},{"@type":"BreadcrumbList","@id":"https:\/\/cancerandpregnancy.com\/staging\/the-use-of-neupogen-filgrastim-or-neulasta-pegfilgrastim-during-pregnancy-when-chemotherapy-is-indicated-for-maternal-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cancerandpregnancy.com\/staging\/"},{"@type":"ListItem","position":2,"name":"The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment"}]},{"@type":"WebSite","@id":"https:\/\/cancerandpregnancy.com\/staging\/#website","url":"https:\/\/cancerandpregnancy.com\/staging\/","name":"Cancer and Pregnancy","description":"Cancer and Pregnancy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cancerandpregnancy.com\/staging\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cancerandpregnancy.com\/staging\/#\/schema\/person\/4193fb10f2572e3f8b9735bdc52aac25","name":"Elyce Cardonick","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cancerandpregnancy.com\/staging\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/460a3f26df5035cf9a773befb634bcc9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/460a3f26df5035cf9a773befb634bcc9?s=96&d=mm&r=g","caption":"Elyce Cardonick"},"url":"https:\/\/cancerandpregnancy.com\/staging\/author\/ecardonick\/"}]}},"_links":{"self":[{"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/posts\/4922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/comments?post=4922"}],"version-history":[{"count":2,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/posts\/4922\/revisions"}],"predecessor-version":[{"id":5540,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/posts\/4922\/revisions\/5540"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/media\/4968"}],"wp:attachment":[{"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/media?parent=4922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/categories?post=4922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cancerandpregnancy.com\/staging\/wp-json\/wp\/v2\/tags?post=4922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}